Treatment of Adenocarcinoma of the Ovary with Combined Immunotherapy and Chemotherapy

Kalpaktsoglou, Pitsa K.; Kondyli, A. P.; Ioannidou, Georgia; Soulpi-Margariti, K. E.; Comninos, Anthony C.; Andritsakis, G.

doi:10.1007/978-1-4613-4352-3_50

Chemotherapy 1976

DOI: 10.1007/978-1-4613-4352-3_50

|View full text |Cite

Treatment of Adenocarcinoma of the Ovary with Combined Immunotherapy and Chemotherapy

Pitsa K. Kalpaktsoglou

A. P. Kondyli

Georgia Ioannidou

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1978

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies we have shown that combined immunotherapy and chemotherapy in mice with transplantable myeloma tumour (3) or spontaneous mammary carcinoma (4, 6, 9) decreases the mortality rate. Also, immunochemotherapy in carcinoma of the reproductive system of the human female results in a rapid amelioration of the patient's general condition and a prolonged recovery (1,7,8,9).…”

mentioning

confidence: 99%

Immunochemotherapy in Adenocarcinoma of the Ovary

Kalpaktsoglou

Ioannidou

Kondyli

et al. 1978

Acta Obstet Gynecol Scand

Self Cite

View full text Add to dashboard Cite

Abstract. Immunochemotherapy combined with total hysterectomy was used in the treatment of 21 cases of adenocarcinoma of the ovary, of which 7 were in stages Ic–IIb, 8 in stage III and 6 in stage IV. Another 6 cases had irradiation with or without hysterectomy, or various other schemes of treatment prior to immunochemotherapy. The immunotherapy depends on stimulation of the humoral and cellular immunity by a battery of antigens (Te, Di–Te, influenza, mumps). Chemotherapy starts by administration of cyclophosphamide three days after each course of immunotherapy. Each course of immunochemotherapy is followed by a period of 10 days free from any medication. The stimulation of the immune mechanism with B. C. G. starts 10 days after the 4th course of immunochemotherapy. This last course of treatment is repeated up to the end of the first year of immunochemotherapy. The same annual scheme of treatment is constantly repeated. The patients are under constant clinical and laboratory follow‐up. The cyclophosphamide is discontinued when ever the WBC falls below 4500 to 4000 per cmm. All patients receive vitamins A, E, C and B complex. All our cases of stages Ic–IIb, and III, with total hysterectomy and without any prior treatment, showed a progressive recovery and are living normal lives. The lymphocytes, the immunoglobulins and the E rosettes returned, in most of our cases to normal levels. The favourable results and the survival rate obtained in cases of cancer without distant metastasis may be attributed to the reduction of the tumour masses by surgery, to the administration of antigens prior to chemotherapy, which seems to diminish the side effects of cyclophosphamide, to the administration of cyclophosphamide in small daily doses to avoid leukopenia and, finally, to the fact that patients are under continuous protective immunochemotherapy.

show abstract

mentioning

confidence: 99%

Immunochemotherapy in Adenocarcinoma of the Ovary

Kalpaktsoglou

Ioannidou

Kondyli

et al. 1978

Acta Obstet Gynecol Scand

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment of Adenocarcinoma of the Ovary with Combined Immunotherapy and Chemotherapy

Cited by 1 publication

References 1 publication

Immunochemotherapy in Adenocarcinoma of the Ovary

Immunochemotherapy in Adenocarcinoma of the Ovary

Contact Info

Product

Resources

About